Just last year, North Carolina officials confronted a projected $507 million deficit in the State Health Plan for Teachers and State Employees. The key is understanding what biosimilars are — and the future promise they hold for taxpayers and patients alike. This gives patients access to the same high-quality treatments at a much lower cost. Too often, elected officials respond to rising healthcare costs by proposing government mandates, price controls or policies that ultimately discourage future medical innovation. Expanding access to biosimilars is exactly that kind of reform — a practical, market-driven policy that strengthens the State Health Plan, protects taxpayers and preserves high-quality care.